Rilapladib (5), a known Lp-PLA2 inhibitor (Figure 3), was able to provide initial evidence supporting Lp-PLA2 as a treatment for AD (Maher-Edwards et al., 2015). The gene discussed is PLA2G7; the disease is Alzheimer disease.